Green Elephant Biotech announced the introduction of the Archimedes® One — Dynamic Adherent Bioreactor, a new platform designed to simplify and scale adherent cell culture processes. The system was developed in close collaboration with Bürkert Fluid Control Systems, combining Green Elephant Biotech’s cultivation technology with Bürkert’s expertise in fluidic control and automation. The collaboration between the two companies began at analytica 2024, when Bürkert’s application management team discovered Green Elephant’s technology. Recognizing the potential to jointly address key challenges in biopharmaceutical manufacturing, Bürkert subsequently joined Green Elephant Biotech as a strategic investor, establishing the foundation for a long-term development partnership.
Together, the teams focused on integrating advanced fluidic and automation technologies with next-generation cell culture systems. The result of this collaboration is the Archimedes® One, the first system in a new category designed specifically for scalable adherent cell cultivation.
Adherent cell processes remain central to many emerging cell and gene therapies but are often difficult to scale. Traditional two-dimensional culture systems rely on manual workflows and large numbers of vessels, while suspension systems frequently require adapting sensitive cell types. Fixed-bed bioreactors can provide scalability but introduce significant hardware complexity and operational overhead.
Archimedes® One takes a biology-first approach. Instead of forcing adherent cells into suspension or complex matrices, the system enables controlled, perfusion-based cultivation using the CellScrew® geometry, providing a large growth surface within a compact footprint. Automated media distribution and integrated cell harvesting reduce manual intervention and support reproducible, standardized workflows.
Through the integration of Bürkert’s fluidic control technologies, the system enables precise control of media and gas flows. In combination with a connected biocontroller, key process parameters such as pH, dissolved oxygen, and temperature can be monitored and controlled, bringing bioreactor-level process control to adherent cell cultivation.
“Cell therapy manufacturing should not require choosing between biological integrity and industrial scalability,” said Joel Eichmann, Co-Founder of Green Elephant Biotech. “With Archimedes® One, we are introducing a platform that aligns process control with adherent cell biology while significantly reducing operational complexity.”
“The collaboration with Green Elephant demonstrates how precise fluidics and automation technologies can open up new possibilities in cell culture technology,” says Hendrik Faustmann, Manager New Business Model Development at Bürkert Fluid Control Systems. “By combining our expertise in automation and system integration with Green Elephant’s cultivation platform, we have created a system architecture that seamlessly integrates fluid management and process control—optimally tailored to the requirements of modern adherent cell processes.”
The system is currently being introduced to the market ahead of its planned commercial launch later this year. In parallel, Green Elephant Biotech is opening an Early Access Program for selected cell therapy companies and CDMOs, providing early access to production units, dedicated technical support, and the opportunity to contribute to application data and case studies ahead of the commercial launch.
“The Early Access Program allows us to work directly with therapy developers and CDMOs as we prepare for commercial launch,” said Felix Wollenhaupt, Co-Founder at Green Elephant Biotech. “Together, we want to demonstrate how Archimedes® One integrates into real manufacturing workflows and supports scalable adherent cell production.”
Green Elephant Biotech and Bürkert Fluid Control Systems will present the dynamic adherent bioreactor together at analytica 2026 in Munich (Stand A1.419), where visitors can learn more about the joint development and experience the system firsthand.
Companies interested in the Early Access Program can apply via: www.greenelephantbiotech.com/eap
About Green Elephant
Green Elephant Biotech was founded with two driving forces: making advanced therapies more accessible by changing how cells are manufactured and making the life sciences industry more sustainable. CellScrew® is a compact 3D-printed system that streamlines adherent cell expansion from research to clinical manufacturing in Cell and Gene Therapies, vaccines, and biologics. With the dynamic adherent bioreactor Archimedes® One, CellScrew® technology is being extended from manual workflows to automated adherent cell manufacturing. The company also applies plant-based bioplastics to conventional labware, including the Green Elephant® microPLAte, a PLA-based 96-well plate. Founded in 2021 as a university spin-off, the growing international team operates from Berlin and Giessen.
More information at www.greenelephantbiotech.com or www.linkedin.com/...
Together, the teams focused on integrating advanced fluidic and automation technologies with next-generation cell culture systems. The result of this collaboration is the Archimedes® One, the first system in a new category designed specifically for scalable adherent cell cultivation.
Adherent cell processes remain central to many emerging cell and gene therapies but are often difficult to scale. Traditional two-dimensional culture systems rely on manual workflows and large numbers of vessels, while suspension systems frequently require adapting sensitive cell types. Fixed-bed bioreactors can provide scalability but introduce significant hardware complexity and operational overhead.
Archimedes® One takes a biology-first approach. Instead of forcing adherent cells into suspension or complex matrices, the system enables controlled, perfusion-based cultivation using the CellScrew® geometry, providing a large growth surface within a compact footprint. Automated media distribution and integrated cell harvesting reduce manual intervention and support reproducible, standardized workflows.
Through the integration of Bürkert’s fluidic control technologies, the system enables precise control of media and gas flows. In combination with a connected biocontroller, key process parameters such as pH, dissolved oxygen, and temperature can be monitored and controlled, bringing bioreactor-level process control to adherent cell cultivation.
“Cell therapy manufacturing should not require choosing between biological integrity and industrial scalability,” said Joel Eichmann, Co-Founder of Green Elephant Biotech. “With Archimedes® One, we are introducing a platform that aligns process control with adherent cell biology while significantly reducing operational complexity.”
“The collaboration with Green Elephant demonstrates how precise fluidics and automation technologies can open up new possibilities in cell culture technology,” says Hendrik Faustmann, Manager New Business Model Development at Bürkert Fluid Control Systems. “By combining our expertise in automation and system integration with Green Elephant’s cultivation platform, we have created a system architecture that seamlessly integrates fluid management and process control—optimally tailored to the requirements of modern adherent cell processes.”
The system is currently being introduced to the market ahead of its planned commercial launch later this year. In parallel, Green Elephant Biotech is opening an Early Access Program for selected cell therapy companies and CDMOs, providing early access to production units, dedicated technical support, and the opportunity to contribute to application data and case studies ahead of the commercial launch.
“The Early Access Program allows us to work directly with therapy developers and CDMOs as we prepare for commercial launch,” said Felix Wollenhaupt, Co-Founder at Green Elephant Biotech. “Together, we want to demonstrate how Archimedes® One integrates into real manufacturing workflows and supports scalable adherent cell production.”
Green Elephant Biotech and Bürkert Fluid Control Systems will present the dynamic adherent bioreactor together at analytica 2026 in Munich (Stand A1.419), where visitors can learn more about the joint development and experience the system firsthand.
Companies interested in the Early Access Program can apply via: www.greenelephantbiotech.com/eap
About Green Elephant
Green Elephant Biotech was founded with two driving forces: making advanced therapies more accessible by changing how cells are manufactured and making the life sciences industry more sustainable. CellScrew® is a compact 3D-printed system that streamlines adherent cell expansion from research to clinical manufacturing in Cell and Gene Therapies, vaccines, and biologics. With the dynamic adherent bioreactor Archimedes® One, CellScrew® technology is being extended from manual workflows to automated adherent cell manufacturing. The company also applies plant-based bioplastics to conventional labware, including the Green Elephant® microPLAte, a PLA-based 96-well plate. Founded in 2021 as a university spin-off, the growing international team operates from Berlin and Giessen.
More information at www.greenelephantbiotech.com or www.linkedin.com/...
